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s APC = antigen-presenting cell; BND = population of cells bound to the surface; EC = endothelial cell; ICAM = intercellular cell-adhesion molecule;
IFN-g = interferon-g; IL = interleukin; MIG = population of cells migrated into collagen gel; MIP = macrophage inflammatory protein; NAD = non-
adherent cell population; PBMC = peripheral blood mononuclear cells; PBS = phosphate-buffered saline; RA = rheumatoid arthritis; TNF-a =
tumour necrosis factor-a.
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Abstract
In our study we characterised the immunophenotype of monocytes that migrated through an
endothelial cell (EC) monolayer in vitro. We found that monocyte migration led to an enhanced
expression of CD11a, CD33, CD45RO, CD54 [intercellular cell-adhesion molecule (ICAM)-1] and
human leucocyte antigen-DR. The most striking increase was observed for ICAM-1 when ECs were
activated with tumour necrosis factor-a and interleukin-1a. The results of our study indicate the
following: (1) there is a characteristic immunophenotype on the surface of monocytes after
transendothelial migration; (2) this phenotype seems to be induced by interactions between
monocytes and ECs; and (3) this change is enhanced by the pretreatment of ECs with cytokines.
Taken together, the results suggest that local cytokine production activating ECs is sufficient to
enhance monocyte migration and that this, in turn, can induce changes consistent with an activated
phenotype known to be interactive between antigen-presenting cells and T cells. These results have
implications for our pathogenetic insights into rheumatoid arthritis.
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Synopsis
Introduction: Acute and chronic inflammation are characterised
by the enhanced migration of leucocytes from the blood vessels
through the endothelium into the extravascular tissue. There are
ample data on the transendothelial migration of lymphocytes
[1–6]. In addition, T cells capable of transendothelial migration
have a characteristic immunophenotype; for instance, migrating
T cells express significantly higher amounts of CD29
(b1-integrin) than cells that do not interact with endothelial cells
(ECs) [7]. In contrast, much less is known about the
extravasation of cells of the monocyte/macrophage lineage.
Under normal conditions, only a few monocytes are able to
migrate from the bloodstream into healthy tissue, where they
differentiate into macrophages [8]. In inflammatory diseases
such as rheumatoid arthritis (RA), monocytes accumulate in the
synovial membrane and contribute significantly to the
pathogenesis of the disease, mainly by secreting cytokines such
as tumour necrosis factor-a (TNF-a) and interleukin-1 (IL-1) [9].
Transendothelial migration of monocytes might also be an
important step in the pathogenesis of non-inflammatory
diseases, for example atherosclerosis [10–12].Several pairs of receptors and counter-receptors that mediate
the interaction of monocytes with ECs have been described
[13–17], but the phenotype of monocytes capable of
transendothelial migration was not defined. Previously we
found an enhanced expression of CD54 [intercellular cell-
adhesion molecule (ICAM)-1] on monocytes that had migrated
through an unstimulated EC monolayer [18].
Aims: In our study we characterised the immunophenotype of
monocytes that migrated through an EC monolayer in an in
vitro model. We found that monocyte migration led to an
enhanced expression of CD11a, CD33, CD45RO, CD54
(ICAM-1) and human leucocyte antigen (HLA)-DR. The most
striking increase was observed for CD54 when ECs were
activated with TNF-a and IL-1a. Our findings of increased
CD54 expression on monocytes that migrated through
endothelium pretreated with TNF-a and IL-1a might be useful
in elucidating the mode of action of therapy with antibodies
against TNF-a and IL-1 in RA and thus might lead to new
avenues of RA therapy in future.
Methods: ECs were isolated from human umbilical cord veins
by digestion with collagenase as described previously [7] and
then cultured. ECs in the third to fifth passage were used.
Peripheral blood mononuclear cells (PBMCs) were prepared
from buffy coats of healthy blood donors by centrifugation over
gradients of Ficoll-Hypaque. PBMCs were prepared
immediately before starting the experiments.
Interactions with ECs in PBMC populations were examined on
hydrated bovine collagen gels in the wells of 16 mm macrowell
tissue culture plates, as described previously [7]. To form a
confluent monolayer on the collagen gels, 5 × 105 ECs per well
were incubated overnight.
To measure monocyte interaction with ECs, PBMCs (3 × 106)
were resuspended in fresh culture medium, layered on top of
collagen gels with and without ECs and incubated at 37°C.
The range of the incubation period was 15 minutes to
24 hours. Nonadherent cells (NAD) were harvested by washing
twice with culture medium. Cells bound to the surface (BND)
were enriched by washing each well twice with warm (37°C)
Puck’s EDTA, twice with warm (37°C) EGTA [0.5 mM EGTA in
phosphate-buffered saline (PBS)] and once with cold (4°C)
Puck’s EDTA. Finally, for the recovery of those cells that had
migrated into the collagen gels (MIG), 0.7 ml of a solution
containing 0.1% collagenase, 1% (v/v) fetal calf serum and
50 mM Hepes buffer was added per well. The collagen gels
were then minced gently with a pipette and incubated for
60 minutes at 37°C, after which the migrated PBMCs were
removed by washing the wells twice with PBS. Each
population (NAD, BND and MIG) was washed, resuspended in
culture medium and counted under a microscope. In some
experiments we studied monocyte migration into plain collagen
gels. In these experiments no ECs were layered on the
collagen gels; in other respects the experiments were
performed exactly as described above.
In some experiments the EC monolayer was preactivated by
incubation with TNF-a, IL-1a, macrophage inflammatory protein
(MIP)-1a or interferon-g (IFN-g). To this end, the medium in
each well was removed and the ECs were incubated for
5 hours at 37°C with or without the respective cytokines or
chemokines (100 IU/ml TNF-a, IL-1a or IFN-g, or 50 ng/ml
MIP-1a). After this 5-hour pretreatment, each well was washed
thoroughly and the migration assay was performed as
described above.
Staining of monocytes was performed with fluorescein
isothiocyanate (FITC)-conjugated antibodies against CD11a,
CD33, CD45RA, CD45RO, CD49d (a4-integrin), CD54
(ICAM-1), CD86, HLA-DR, CD45RB and CD62L (L-selectin)
(functions and ligands of these surface markers are shown in
Table 1). To distinguish monocytes from other immune cells, all
samples were counterstained with a phycoerythrin-labelled anti-
CD14 monoclonal antibody. Cells (3 × 105 to 4 × 105 per
Arthritis Research    Vol 3 No 2 Grisar et al
Table 1
Description of the ligands and functions of the surface markers studied
Surface marker Designation Ligand(s) Function
CD11a CD54, CD102 Adhesion, T cell development
CD33 Sialylated glycoproteins ? Functions in haematopoesis
CD45RA Signal transduction
CD45RB Signal transduction
CD45RO Signal transduction
CD49d a4-integrin VCAM-1, fibronectin, MAdCAM-1, invasin Adhesion, embryonic development
CD54 ICAM-1 LFA-1 (CD11a/CD18), Mac-1  Adhesion, leucocyte transendothelial migration, 
(CD11b/CD18), CD43 signal transduction
CD62L L-selectin DNAd (CD34, GlyCAM-1, MAdCAM-1) Adhesion; leucocyte homing, rolling and 
extravasation
CD86 B 7-2 CD28, CD152 T cell interaction with dendritic cells and B cells, 
B cell co-stimulationsample) were incubated at 4°C for 30 minutes. Cells were then
pelleted and resuspended in 250 ml of PBS before analysis was
performed on a flow cytometer. All results are expressed as the
respective mean fluorescence intensity among CD14-positive
cells. Because not only monocytes but also ECs express CD54
(ICAM-1), in the analyses of the expression of CD54 on
monocytes by fluorescence-activated cell sorting, monocytes
were defined by both the scatter profile and the expression of
CD14. In addition, ECs, which are considerably larger, were
excluded by size.
All data are presented as means ± SD. Paired Student’s t-tests
were used for comparisons.
Results: In initial experiments we studied the time course of
PBMC migration into plain or EC-coated collagen gels,
respectively. As shown in Fig. 1, the presence of an
endothelium clearly facilitated the migration of PBMCs: after
30 minutes the percentage of PBMCs that had migrated was
twice as high as that in the absence of ECs. After 2 hours,
about 40% of the PBMCs could be recovered from collagen
gels coated with an EC layer, whereas only 24% of PBMCs
had migrated into plain collagen gels. Prolonging the
incubation time to 24 hours allowed further migration of
PBMCs only in the absence of ECs, but did not significantly
increase the extent of EC-mediated migration.
The results and the statistical evaluation of the phenotypic
analysis of monocytes recovered in various fractions of the
migration assay are shown in Table 2. The expression of
CD11a, CD33, CD45RO, CD54 and HLA-DR was significantly
higher in MIG than in NAD. When compared with BND, these
markers, and also CD45RB and CD62L, were significantly
elevated in MIG. NAD, BND and MIG were incubated with
collagenase for the same durations to control for possible cell
activation by the collagenase treatment; the expression of
adhesion molecules was similar to that on untreated cells.
We also studied the capacity for monocyte migration into plain
collagen gels, that is, in the absence of an endothelium. No
significant difference in surface marker expression was
observed when migrated monocytes were compared with any
other fraction.
It has been reported that cytokines such as TNF-a, IL-1a and
IFN-g and also the chemokine MIP-1a can enhance the
transendothelial migration of monocytes [19,20]. We were
therefore interested to investigate whether pretreatment of the
ECs with these factors would be sufficient to enhance the
transendothelial migration of monocytes and/or to induce
Available online http://arthritis-research.com/content/3/2/127
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
m
e
e
t
i
n
g
 
a
b
s
t
r
a
c
t
s
Figure 1
Endothelium enhances monocyte migration. The percentages of
peripheral blood mononuclear cells (PBMCs) migrated in the absence
(white columns) or presence (black columns) of endothelial cells are
shown at different time points. Results are means ± SD for at least
three independent experiments. Asterisks denote significant (P < 0.05)
differences between the percentages of cells migrated in the absence
of endothelium and in its presence.
Table 2
Surface marker expression on different monocyte populations
Marker Initial NAD BND MIG
CD11a 312 ± 138 301 ± 154‡ 273 ± 150 362 ± 187*†
CD33 138 ± 63 130 ± 49‡ 118 ± 49 148 ± 70*†
CD45RA 24 ± 15 25 ± 11 27 ± 11 46 ± 47
CD45RB 397 ± 149 367 ± 135‡ 326 ± 134 375 ± 154†
CD45RO 64 ± 35 80 ± 44 79 ± 50 111 ± 57*†
CD49d 56 ± 10 53 ± 10 53 ± 12 65 ± 28 
CD54 41 ± 32 36 ± 12 35 ± 15 58 ± 33*†
CD62L 22 ± 24 30 ± 24 29 ± 26 44 ± 33†
CD86 26 ± 19 36 ± 30 66 ± 103 26 ± 14
HLA-DR 174 ± 83 186 ± 89 207 ± 104 326 ± 254*†
Data shown are fluorescence intensities (means  ±  SD) of the initial population and the nonadherent (NAD), bound (BND) and migrated (MIG)
monocytes. In all 14 experiments performed, the migration period was 30 minutes; the endothelium was not pretreated. *Statistical significance 
(P < 0.05) MIG compared with NAD. †Statistical significance (P < 0.05) MIG compared with BND. ‡Statistical significance (P < 0.05) NAD
compared with BND.Arthritis Research    Vol 3 No 2 Grisar et al
changes in their expression of surface markers. Figure 2 shows
that pretreatment of the endothelium with any of the cytokines
led to a consistent and significant increase in the number of
migrated mononuclear cells in comparison with simultaneously
performed control experiments in which the endothelium was not
pretreated. Pretreatment with IL-1a was the most effective,
resulting in a 132% increase in migrated cells (P < 0.001). The
respective values for the other cytokines were as follows:
MIP-1a, 194% (P = 0.043); TNF-a, 193% (P = 0.006); IFN-g,
136% (P = 0.016).
Pretreatment of ECs with TNF-a led to a significant decrease in
CD45RO and HLA-DR on migrated monocytes. In contrast,
CD54 (ICAM-1) was significantly increased on monocytes that
migrated through endothelium pretreated with TNF-a or IL-1a
in comparison with migration through untreated endothelium
(Figs 3 and 4, Table 3).
When ECs were pretreated with IFN-g or MIP-1a, no
statistically significant change in monocyte surface markers
was observed (Table 3).
Discussion: Our experiments characterised the immuno-
phenotype of monocytes that migrated through EC monolayers.
Several surface molecules (CD11a, CD33, CD45RO, ICAM-1
and HLA-DR) were significantly increased on the migrated
monocytes in comparison with the nonadherent population.
Figure 3
Migration through endothelium increases CD54 expression on
monocytes. Histograms show the CD54 mean fluorescence intensity
(mfi) of monocytes that migrated through untreated endothelium (grey
line in each panel), or endothelium pretreated with tumour necrosis
factor-a (black line in middle panel) or interleukin-1a (black line in
bottom panel). CD54 mfi of the nonadherent monocyte fraction is
shown by a dotted line (top panel), isotype controls are shown by a
thin black line in each panel. The experiment shown is representative of
three independent experiments.
Figure 2
Monocyte migration is increased after the pretreatment of ECs with
cytokines. Confluent monolayers of ECs that were formed on collagen
gels were simultaneously incubated without cytokines (control) and
with tumour necrosis factor-a (TNF-a) (a), interleukin-1a (IL-1a) (b),
interferon-g (IFN-g) (c) or macrophage inflammatory protein-1a (MIP-
1a) (d). The percentages of migrated peripheral blood mononuclear
cells (PBMCs) after a migration period of 30 minutes are shown.
Statistical significance: (a) P = 0.006; (b) P < 0.001; (c) P = 0.016;
(d) P = 0.043.Available online http://arthritis-research.com/content/3/2/127
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The differences in the immunophenotype between migrating
and nonadherent monocytes could be explained either by the
preferential migration of a particular subset of monocytes or as
a result of the interaction of monocytes with the endothelium. If
the observed alterations in the immunophenotype of migrating
monocytes had been due to the preferential migration of a
particular subset, we would have expected a depletion of this
subset in the nonadherent population. This did not occur; all
surface markers studied were expressed to similar extents on
the nonadherent and initial populations (see Table 2). The
notion that the process of transendothelial migration leads to
an upregulation of certain surface markers on monocytes is
also supported by the fact that the expression of most markers
was significantly higher in the migrated cells than in the bound
cells (see Table 2). Taken together, our results suggest that
transendothelial migration induces the activation or maturation
of monocytes.
As described previously [19,20], we found that pretreatment of
the endothelium with certain chemokines or cytokines
enhanced transendothelial migration. The most striking
phenotypic changes were seen for ICAM-1 expression, when
ECs were pretreated with TNF-a and IL-1a (see Table 3 and
Figs 3 and 4). In contrast, MIP-1a pretreatment did not change
the monocyte phenotype investigated here. In the light of
enhanced migration through MIP-1a-prestimulated endo-
thelium, these results suggest a dichotomy of cytokine/
chemokine effects on migration compared with surface marker
expression: ECs activated with TNF-a and IL-1a seem to lead
to an upregulation of both monocyte migration and surface
marker expression, whereas MIP-1a only enhances migration, a
finding that is compatible with the chemotactic chemokine
nature of MIP-1a. Alternatively, MIP-1a could have been
trapped in the collagen gel, acting as a chemotactic gradient
directly on monocytes rather than via ECs. Thus TNF-a and
IL-1a seem to mediate different proinflammatory events from
those mediated by MIP-1a.
Our observations of increased expression of ICAM-1 on
migrated monocytes after the pretreatment of ECs with TNF-a
and IL-1a are especially remarkable because these cytokines
are important in the pathogenesis of inflammation. In RA,
TNF-a and IL-1 blockade showed an unequivocal therapeutic
effect [21–23]. In addition, ICAM-1 and E-selectin levels of
patients with RA who had received anti-TNF-a therapy
decreased within a few days of the initiation of therapy [24].
Figure 4
Cytokine-pretreated endothelium increases CD54 expression on
monocytes. The fluorescein isothiocyanate (FITC) mean fluorescence
intensity (mfi) of monocytes that migrated through endothelium
pretreated with tumour necrosis factor-a (TNF-a) (a) or interleukin-1a
(IL-1a) (b) is compared with the mfi of monocytes that simultaneously
migrated through untreated endothelium (control). Statistical
significance: (a) P = 0.043; (b) P = 0.019.
Table 3
Changes in surface phenotypes of migrated monocytes
Marker TNF-a IFN-g IL-1a MIP-1a
CD11a 96 ± 8 106 ± 16 76 ± 41 87 ± 9
CD33 74 ± 49 105 ± 7 107 ± 16 165 ± 107
CD45RA 52 ± 53 134 ± 77 73 ± 65 63 ± 34
CD45RB 91 ± 7 86 ± 4 79 ± 44 84 ± 23
CD45RO 80 ± 9* 98 ± 6 92 ± 8 78 ± 54
CD49d 92 ± 31 83 ± 26 81 ± 18 87 ± 21
CD54 199 ± 55* 111 ± 38 173 ± 27* 76 ± 31
CD62L 88 ± 10 52 ± 39 105 ± 42 103 ± 16
CD86 103 ± 25 219 ± 134 69 ± 25 90 ± 36
HLA-DR 86 ± 2* 88 ± 18 87 ± 20 82 ± 52
The changes in individual surface markers after pretreatment of endothelial cells (ECs) with the indicated cytokines and chemokines are shown as
percentages of control experiments with untreated ECs. All results were derived from at least three independent experiments for each cytokine or
chemokine. HLA-DR, human leucocyte antigen-DR; IFN-g, interferon-g; IL-1a, interleukin-1a; MIP-1a, macrophage inflammatory protein-1a; TNF-a;
tumour necrosis factor-a. *Statistically significant change (P < 0.05) compared with cells that migrated through untreated ECs.Introduction
Acute and chronic inflammation are characterised by an
enhanced migration of leucocytes from the blood vessels
through the endothelium into the extravascular tissue.
There are ample data on the transendothelial migration of
lymphocytes [1–6]. In addition, T cells capable of trans-
endothelial migration have a characteristic immunopheno-
type; for instance, migrating T cells express significantly
higher amounts of CD29 (b1-integrin) than cells that do
not interact with endothelial cells (ECs) [7]. In contrast,
much less is known about the extravasation of cells of the
monocyte/macrophage lineage. Under normal conditions,
only a few monocytes are able to migrate from the blood-
stream into healthy tissue, where they differentiate into
macrophages [8]. In inflammatory diseases such as
rheumatoid arthritis (RA), monocytes accumulate in the
synovial membrane and contribute significantly to the
pathogenesis of the disease, mainly by secreting cytokines
such as tumour necrosis factor-a (TNF-a) and interleukin-1
(IL-1) [9]. Transendothelial migration of monocytes might
also be an important step in the pathogenesis of non-
inflammatory diseases, for example atherosclerosis
[10–12].
Several pairs of receptors and counter-receptors that
mediate the interaction of monocytes with ECs have been
described [13–17], but the phenotype of monocytes
capable of transendothelial migration was not defined.
Previously we found an enhanced expression of CD54
[intercellular cell-adhesion molecule (ICAM)-1] on mono-
cytes that had migrated through an unstimulated EC
monolayer [18].
It was the aim of the present study to perform a detailed
characterisation of the immunophenotype of transendothe-
lially migrated monocytes.
Materials and methods
Cell cultures
ECs were isolated from human umbilical cord veins by
digestion with collagenase as described previously [7].
The culture medium consisted of MCDB-M 104 glutamine
(Gibco, Paisley, UK) supplemented with 20% (v/v) fetal
calf serum (FCS), 24 µg/ml EC growth supplement (TC
Laevosan, Vienna, Austria), 50 IU/ml heparin, 2 mM L-glut-
amine (Gibco), penicillin (100 IU/ml; Gibco) and strepto-
mycin (100 µg/ml; Gibco). ECs in the third to fifth passage
were used.
Preparation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were pre-
pared from buffy coats of healthy blood donors by centrifu-
gation over gradients of Ficoll-Hypaque (Histopaque R,
Sigma, Vienna, Austria). PBMCs were prepared immedi-
ately before starting the experiments.
Monocyte-EC binding and transendothelial migration
Interactions with ECs in PBMC populations were exam-
ined on hydrated bovine collagen gels in the wells of
16 mm macrowell tissue culture plates, as described pre-
viously [7]. In brief, the collagen gels were made of 50%
(v/v) bovine collagen (Vitrogen 100; Collagen Biomateri-
als, Palo Alto, California, USA), 7% (v/v) NaOH, 10%
(v/v) 10 × phosphate-buffered saline (PBS; Gibco) and
33% (v/v) distilled water. To form a confluent monolayer
on the collagen gels, 5 × 105 ECs per well were incu-
bated overnight.
To measure monocyte interaction with ECs, PBMCs
( 3×1 0 6) were resuspended in fresh culture medium,
layered on top of collagen gels with and without ECs and
incubated at 37°C. The range of the incubation period
was 15 minutes to 24 hours. Nonadherent cells (NAD)
Arthritis Research    Vol 3 No 2 Grisar et al
Previous findings indicate that TNF-a and IL-1a induce an
upregulation of the ICAM-1 counter-receptor on ECs [25]. This
is consistent with the increase in cell migration found in our
experiments and the altered expression of ICAM-1 on
monocytes. Because the classic ICAM-1 counter-receptors
LFA-1 and Mac-1 have not been detected on ECs, the
existence of another ICAM-1 ligand, one that facilitates the
transendothelial migration of monocytes, remains possible.
The reported changes indicate that, after migration, monocytes
could become more liable to interact with T cells (which are
known to enhance LFA-1 expression in the presence of TNF-a).
This interaction might lead to a further mutual stimulation of
T cells and macrophages. In fact the ligand–counterligand
system consisting of LFA-1 and ICAM-1 also is one co-
stimulatory pathway involved in interactions between antigen-
presenting cells (APCs) and T cells [26]. Because our results
demonstrate that both ICAM-1 and HLA-DR are upregulated
on migrated monocytes, their function as APCs and possible
ability to communicate with T cells, might be facilitated after
transendothelial migration. Thus, this observation also supports
previous notions on the importance of T cells in the
pathogenesis of RA [27–29].
In summary, our findings indicate that monocyte migration is
accompanied by changes in function-associated surface
antigens and that TNF-a and IL-1a in particular increase the
number of migrating monocytes and lead to an enhanced
expression of certain surface markers involved in cell–cell
interactions. These events might not only be partly
responsible for the high inflammatory activity in RA synovium;
they also suggest that ECs have a pivotal role in these
processes and thus might constitute an important
therapeutic target.
Full articlewere harvested by washing twice with culture medium.
Cells bound to the surface (BND) were enriched by
washing each well twice with warm (37°C) Puck’s EDTA,
twice with warm (37°C) EGTA (0.5 mM EGTA in PBS)
and once with cold (4°C) Puck’s EDTA. Finally, for the
recovery of those cells that had migrated into the collagen
gels (MIG), 0.7 ml of a solution containing 0.1% collage-
nase (Sigma), 1% (v/v) FCS and 50 mM Hepes buffer
(Gibco) was added per well. The collagen gels were then
gently minced with a pipette and incubated for 60 minutes
at 37°C, after which the migrated PBMCs were removed
by washing the wells twice with PBS. Each population
(NAD, BND and MIG) was washed, resuspended in
culture medium and counted by microscope. In some
experiments monocyte we studied migration into plain col-
lagen gels. In these experiments no ECs were layered on
the collagen gels; in other respects the experiments were
performed exactly as described above.
Pretreatment of ECs
In some experiments the EC monolayer was preactivated
by incubation with TNF-a (Pharma Biotechnology, Han-
nover, Germany), IL-1a, macrophage inflammatory
protein-1a (MIP-1a) or interferon-g (IFN-g) (all purchased
from Serotec, Oxford, UK). To this end, the medium in
each well was removed and the ECs were incubated for
5 hours at 37°C with or without the respective cytokines
or chemokines (100 IU/ml TNF-a, IL-1a or IFN-g, or
50 ng/ml MIP-1a). After this 5-hour pretreatment, each
well was washed thoroughly and the migration assay was
performed as described above.
Analysis of monocyte surface markers by dual colour
flow cytometry
Staining of monocytes was performed with fluorescein
isothiocyanate (FITC)-conjugated antibodies against
CD11a, CD33, CD45RA, CD45RO, CD49d (a4-integrin),
CD54 (ICAM-1), CD86, HLA-DR (all purchased from
Serotec), CD45RB (Dako, Glostrup, Denmark) and
CD62L (L-selectin) (Becton–Dickinson, San Jose, Califor-
nia, USA) (functions and ligands of these surface markers
are shown in Table 1). To distinguish monocytes from
other immune cells, all samples were counterstained with
a phycoerythrin-labelled anti-CD14 monoclonal antibody.
Cells (3 × 105 to 4 × 105 per sample) were incubated at
4°C for 30 minutes. Cells were then pelleted and resus-
pended in 250 ml of PBS before analysis was performed
on a flow cytometer (FACScan; Becton–Dickinson). All
results are expressed as the respective mean fluores-
cence intensity among CD14-positive cells. Because not
only monocytes but also ECs express CD54 (ICAM-1), in
the analyses of the expression of CD54 on monocytes by
fluorescence-activated cell sorting, monocytes were
defined by both the scatter profile and the expression of
CD14. In addition, ECs, which are considerably larger,
were excluded by size.
Statistics
All data are presented as means ± SD. Paired Student’s
t-tests were used for comparisons.
Results
Transendothelial migration of PBMCs
In initial experiments we studied the time course of PBMC
migration into plain or EC-coated collagen gels, respec-
tively. As shown in Fig. 1, the presence of an endothelium
clearly facilitated the migration of PBMCs: after 30 minutes
the percentage of PBMCs that had migrated was twice as
high as that in the absence of ECs. After 2 hours, about
40% of the PBMCs could be recovered from collagen gels
coated with an EC layer, whereas only 24% PBMCs had
migrated into plain collagen gels. Prolonging the incubation
time to 24 hours allowed further migration of PBMCs only
in the absence of ECs, but did not significantly increase the
extent of EC-mediated migration.
Phenotypic analysis of monocytes capable of
transendothelial migration
The results and the statistical evaluation of the phenotypic
analysis of monocytes recovered in various fractions of the
migration assay are shown in Table 2. The expression of
CD11a, CD33, CD45RO, CD54 and HLA-DR was signifi-
cantly higher in MIG than in NAD. When compared with
BND, these markers, and also CD45RB and CD62L, were
significantly elevated in MIG. NAD, BND and MIG were
incubated with collagenase for the same durations to
control for possible cell activation by the collagenase
treatment; the expression of adhesion molecules was
similar to that on untreated cells.
Phenotypic analysis of monocytes migrated into plain
collagen gels
We also studied the capacity for monocyte migration into
plain collagen gels, that is, in the absence of an endothe-
lium. No significant difference in surface marker expres-
sion was observed when migrated monocytes were
compared with any other fraction.
Effect of pretreatment of ECs on the transendothelial
migration of monocytes
It has been reported that cytokines such as TNF-a, IL-1a
and IFN-g and also the chemokine MIP-1a can enhance
the transendothelial migration of monocytes [19,20]. We
were therefore interested to investigate whether pretreat-
ment of the ECs with these factors would be sufficient to
enhance the transendothelial migration of monocytes
and/or to induce changes in their expression of surface
markers. Figure 2 shows that pretreatment of the endothe-
lium with any of the cytokines led to a consistent and sig-
nificant increase in the number of migrated mononuclear
cells in comparison with simultaneously performed control
experiments in which the endothelium was not pretreated.
Pretreatment with IL-1a was the most effective, resulting
Available online http://arthritis-research.com/content/3/2/127
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sin a 132% increase in migrated cells (P < 0.001). The
respective values for the other cytokines were as folows:
MIP-1a, 194% (P = 0.043); TNF-a, 193% (P = 0.006);
IFN-g, 136% (P = 0.016).
Effect of pretreatment of ECs on the immunophenotype
of migrated monocytes
Pretreatment of ECs with TNF-a led to a significant
decrease in CD45RO and HLA-DR on migrated mono-
cytes. In contrast, CD54 (ICAM-1) was significantly
increased on monocytes that migrated through endothelium
pretreated with TNF-a or IL-1a in comparison with migration
through untreated endothelium (Figs 3 and 4, Table 3).
When ECs were pretreated with IFN-g or MIP-1a, no sta-
tistically significant change in monocyte surface markers
was observed (Table 3).
Discussion
Our experiments characterised the immunophenotype of
monocytes that migrated through EC monolayers. Several
surface molecules (CD11a, CD33, CD45RO, ICAM-1 and
HLA-DR) were significantly increased on the migrated
monocytes in comparison with the nonadherent popula-
tion. The differences in the immunophenotype between
migrating and nonadherent monocytes could be explained
either by the preferential migration of a particular subset of
monocytes or as a result of the interaction of monocytes
with the endothelium. If the observed alterations in the
immunophenotype of migrating monocytes had been due
to the preferential migration of a particular subset, we
would have expected a depletion of this subset in the non-
adherent population. This did not occur; all surface
markers studied were expressed to similar extents on the
nonadherent and initial populations (see Table 2). The
notion that the process of transendothelial migration leads
to an upregulation of certain surface markers on mono-
cytes is also supported by the fact that the expression of
most markers was significantly higher in the migrated cells
than in the bound cells (see Table 2). Taken together, our
results suggest that transendothelial migration induces the
activation or maturation of monocytes.
The fact that monocytes that migrated into collagen gels
without an endothelium failed to change their immunophe-
notype indicates that monocyte differentiation might be
signalled not by the migration step itself or by the pres-
ence of collagen but by interactions between monocytes
and ECs. Additional control experiments proved that colla-
genase itself did not lead to any of the observed changes.
Recent observations with lymphocytes indicate that at
least some of the changes could be due to the transfer of
surface molecules from ECs to monocytes [30]. It is not
known at present whether this is also true of monocytes.
For T cells a preferential migration of a CD45RO-positive
subset is already known [2,7]. Here we found an upregula-
tion of CD45RO in the whole population of migrated
monocytes; the significance of this finding is not clear and
also merits further elucidation.
CD11a on monocytes, and its ligand ICAM-1 on ECs, are
known to be important for adhesion in monocyte migration
[31]; our observation of upregulated CD11a on monocytes
after transendothelial migration is in line with these data.
Audran et al [32] compared the difference in the expres-
sion of certain adhesion molecules between monocytes
and differentiated macrophages. They found that ICAM-1
increased during differentiation and showed stronger
expression on macrophages than on monocytes. More-
over, monocytes and macrophages that were recovered
from inflammatory sites, such as from the synovial fluid of
patients with RA [33], from bronchial biopsies of patients
with asthma [34] or from peritoneal fluid of patients with
peritonitis [35], had a high expression of ICAM-1. These
findings and our results therefore suggest that the
immunophenotype of macrophages or monocytes recov-
ered from inflammatory lesions is determined, at least in
part, by the process of transendothelial migration.
As described previously [19,20], we found that pretreat-
ment of the endothelium with certain chemokines or
cytokines enhanced transendothelial migration. The most
striking phenotypic changes were seen for ICAM-1
expression, when ECs were pretreated with TNF-a and
IL-1a (see Table 3 and Figs 3 and 4). In contrast, MIP-1a
pretreatment did not change the monocyte phenotype
investigated here. In the light of enhanced migration
through MIP-1a-prestimulated endothelium, these results
suggest a dichotomy of cytokine/chemokine effects on
migration compared with surface marker expression: ECs
activated with TNF-a and IL-1a seem to lead to an upreg-
ulation of both monocyte migration and surface marker
expression, whereas MIP-1a only enhances migration, a
finding that is compatible with the chemotactic chemokine
nature of MIP-1a. Alternatively, MIP-1a could have been
trapped in the collagen gel, acting as a chemotactic gradi-
ent directly on monocytes rather than via ECs. Thus TNF-a
and IL-1a seem to mediate different proinflammatory
events from those mediated by MIP-1a.
Generally, the influence of ECs on monocytes could be
explained in two ways: either such signals are provided by
cell–cell interaction via pairs of receptors and counter-
receptors during the process of migration, or, alternatively,
ECs could secrete chemoattractants. However, in the
latter case we would instead expect similar effects on the
bound subpopulation as well as a higher percentage of
EC-bound monocytes.
Our observations of increased expression of ICAM-1 on
migrated monocytes after the pretreatment of ECs with
Arthritis Research    Vol 3 No 2 Grisar et alTNF-a and IL-1a are especially remarkable because these
cytokines are important in the pathogenesis of inflamma-
tion. In RA, TNF-a and IL-1 blockade showed an unequivo-
cal therapeutic effect [21–23]. In addition, ICAM-1 and
E-selectin levels of patients with RA who had received
anti-TNF-a therapy decreased within a few days of the ini-
tiation of therapy [24].
Previous findings indicate that TNF-a and IL-1a induce an
upregulation of the ICAM-1 counter-receptor on ECs [25].
This is consistent with the increase in cell migration found
in our experiments and the altered expression of ICAM-1
on monocytes. Because the classic ICAM-1 counter-
receptors LFA-1 and Mac-1 have not been detected on
ECs, the existence of another ICAM-1 ligand, one that
facilitates the transendothelial migration of monocytes,
remains possible.
The reported changes indicate that, after migration, mono-
cytes could become more liable to interact with T cells
(which are known to enhance LFA-1 expression in the
presence of TNF-a). This interaction might lead to a
further mutual stimulation of T cells and macrophages. In
fact the ligand–counterligand system consisting of LFA-1
and ICAM-1 also is one co-stimulatory pathway involved in
interactions between antigen-presenting cells (APCs) and
T cells [26]. Because our results demonstrate that both
ICAM-1 and HLA-DR are upregulated on migrated mono-
cytes, their function as APCs and possible ability to
communicate with T cells, might be facilitated after
transendothelial migration. Thus, this observation also sup-
ports previous notions on the importance of T cells in the
pathogenesis of RA [27–29].
We also observed an upregulation of CD33 on migrated
monocytes. In this respect it is noteworthy that Randolph
et al. reported monocyte differentiation into dendritic cells
after reverse transmigration [36]; furthermore, it was
shown that dendritic cells isolated from RA synovial fluid
expressed high levels of CD33 [37]. Because it is known
that the synovial lesions in RA are enriched in dendritic
cells [37], it is tempting to speculate that some CD33
high monocytes might differentiate into dendritic cells in
inflammatory sites.
Previous studies investigated the transendothelial migra-
tion of lymphocytes in particular T cells. For both mono-
cytes and T cells the presence of an endothelium
facilitated the migration into collagen gels; however, in
contrast with the monocyte situation, the capacity of
T cells is an intrinsic ability of certain subpopulations, for
example CD4-positive memory cells [7]. Interestingly, the
activation of ECs by IL-1 and IFN-g shows the same migra-
tion-enhancing effect on T cells as seen here for mono-
cytes [7,38]. Oppenheimer-Marks et al [2,39] reported
that ICAM-1 on T cells promoted binding and migration
through non-activated endothelium. This conclusion is
consistent with our results: ICAM-1 seems to be a pivotal
adhesion molecule in the transendothelial migration of
both monocytes and T cells. Moreover, in a study in vivo it
was observed that the application of monoclonal antibod-
ies against ICAM-1 induced T cell hyporesponsiveness in
patients with RA [40] and led to a clinical benefit in
patients with early or subacute RA.
In summary, our findings indicate that monocyte migration
is accompanied by changes in function-associated
surface antigens and that TNF-a and IL-1a in particular
increase the number of migrating monocytes and lead to
an enhanced expression of certain surface markers
involved in cell–cell interactions. These events might not
only be partly responsible for the high inflammatory activity
in RA synovium; they also suggest that ECs have a pivotal
role in these processes and thus might constitute an
important therapeutic target.
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